Meeting
2017 Gastrointestinal Cancers Symposium
Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).
Authors
Howard S. Hochster
Yale Cancer Center, New Haven, CT
Howard S. Hochster , Johanna C. Bendell , James M. Cleary , Paul Foster , Wei Zhang , Xian He , Genevive Hernandez , Koho Iizuka , S. Gail Eckhardt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01633970
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 673)
DOI
10.1200/JCO.2017.35.4_suppl.673
Abstract #
673
Poster Bd #
H3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.
First Author: Dale Randall Shepard
Poster
2022 ASCO Annual Meeting
TALENTop: A multicenter, randomized study evaluating the efficacy and safety of hepatic resection for selected hepatocellular carcinoma with macrovascular invasion after initial atezolizumab plus bevacizumab treatment.
First Author: Hui-Chuan Sun
Poster
2022 ASCO Annual Meeting
NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
First Author: Naoki Furuya
Poster
2021 ASCO Annual Meeting
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.
First Author: Valeriy Vladimirovich Breder